Loading data for HUMA — first visit, this takes a few seconds.

アラート

Humacyte Inc. (HUMA)

NasdaqGS: HUMA · リアルタイム株価 · USD

0.70

+0.04 (6.06%)

終値時点： Aug 27, 2026, 8:00 PM

0.71

+2.21%

時間外: 5:52 PM

株価、主要な数字、最新ニュースをひとまとめにしたページです。

6.06% (1D)

データがありません

買気配	0.51
時価総額	192.43M
売上高（TTM）	2.12M
純利益（TTM）	-96.67M
	2.47
	-0.52
	n/a
	-2.8
PBR（TTM）	13.32
PSR（TTM）	90.73
決算発表日	Nov 12, 2026

売気配	0.88
出来高	5,905,985
平均出来高（20日）	11,136,119
始値	0.66
前日終値	0.66
当日レンジ	0.66 - 0.73
52週レンジ	0.53 - 2.55
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

HUMAについて

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign...

[続きを読む]

業種 Biotechnology

セクター Healthcare

IPO日 Dec 1, 2020

従業員数 184

上場取引所 NasdaqGS

ティッカー HUMA

ウェブサイト https://www.humacyte.com

企業情報の全文

業績

2025年のHumacyteの売上高は2.04Mで、前年の0からundefined%の増加でした。利益は-40.83Mで、-72.54%の減少でした。

財務諸表

決算サプライズ

HumacyteはAug 12, 2026に四半期決算を発表しました：

売上高は $495K で、予想を下回りました $0, うち -4.26% の前年比減少.
EPSは -0.16 で、予想を下回りました -0.06, うち 33.33% の前年比増加にあたります.

次回決算発表

Humacyte Inc.の決算発表予定日は Nov 12, 2026, 寄り付き前の予定です。
アナリストの売上高予想は ... アップグレード

ニュース

1週間前 · Motley Fool

Humacyte (HUMA) Q2 2026 Earnings Call Transcript

Phase III trial shows 91 more catheter-free days for dialysis patients.

2週間前 · Simply Wall St.

Humacyte (HUMA) Faces A Fresh Test As Its $4 Fair Value Narrative Holds

Humacyte earnings update and stock context Humacyte (HUMA) reported second quarter 2026 results that included revenue of US$0.406 million and a net loss of US$36.8 million, alongside recent Nasdaq com...

2週間前 · Simply Wall St.

Humacyte (HUMA) Stock Looks Stretched On Book Value Yet Reasonable After A 93% Fall

Humacyte stock has had a very rough run over the last several years, and current valuation checks now lean toward the shares looking expensive rather than like a clear bargain. Humacyte has declined 9...

2週間前 · Simply Wall St.

Humacyte (HUMA) Reports Stronger Phase 3 Dialysis Results In Women

Humacyte (NasdaqGS:HUMA) reported Phase 3 dialysis access data showing its acellular tissue engineered vessel outperformed standard of care for female patients. The company plans to file a supplementa...

2週間前 · GuruFocus.com

Humacyte Inc (HUMA) (Q2 2026) Earnings Call Highlights: Strong Trial Results and Strategic ...

Despite a slow commercial quarter, the company's positive Phase III dialysis data and upcoming sBLA submission position it for significant growth in 2027.

2ページ中1ページ

Humacyte Inc. (HUMA)